ImageneBio, Inc. (IMA) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report covers the period ended September 30, 2025. ImageneBio, Inc. (formerly Ikena Oncology, Inc.) is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases. The company's sole product candidate in clinical development is IMG-007, a non-depleting anti-OX40 monoclonal antibody for atopic dermatitis (AD) and other indications.
On July 25, 2025, the company completed a reverse recapitalization merger with Legacy Inmagene Biopharmaceuticals. Legacy Inmagene was deemed the accounting acquirer. Concurrently, the company divested its non-IMG-007 assets (the "Non-OX40 Divestiture") to a related party, Miragene Inc., in exchange for a promissory note.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| License Revenue | $0 | $3.5 million | $0.8 million | $3.5 million |
| Total Operating Expenses | $26.6 million | $5.5 million | $40.7 million | $34.4 million |
| Net Loss | $(24.8) million | $(3.2) million | $(38.4) million | $(31.8) million |
| Cash & Cash Equivalents | $103.2 million (as of Sept 30, 2025) | |||
| Marketable Securities | ||||
| Total Liquidity | $142.6 million | |||
| Debt | $0 (Term loan forgiven at merger) |
Note: The company reported a net loss attributable to common stockholders of $(25.6) million for Q3 2025 and $(45.5) million for the nine months ended September 30, 2025.
Material Changes vs. Prior Period
- Revenue Decline: License revenue dropped to zero in Q3 2025 compared to $3.5 million in Q3 2024, which included a non-refundable upfront payment from the IMG-013 Agreement. YTD 2025 revenue of $0.8 million stemmed from a settlement of the IMG-008 Agreement.
- Expense Surge: Operating expenses increased significantly in Q3 2025 ($26.6M vs $5.5M in Q3 2024). This was primarily driven by a one-time $15.3 million stock-based compensation expense recognized upon the closing of the merger (accelerated vesting of awards). Excluding this non-cash item, operating expenses were lower than the prior year.
- Liquidity Transformation: Cash and cash equivalents increased from $12.1 million at year-end 2024 to $103.2 million at September 30, 2025. This increase was fueled by the merger, which included a $75.0 million PIPE financing and the acquisition of Ikena's cash assets ($54.6 million).
- Debt Elimination: A $22.5 million term loan outstanding at December 31, 2024, was fully forgiven upon the consummation of the merger in July 2025.
Guidance, Outlook, and Risks
- Clinical Outlook: IMG-007 is in Phase 2b dose-finding for atopic dermatitis, with topline data expected in 2027. The company plans to submit a protocol amendment to expand dosing regimens. Future indications under exploration include alopecia areata, asthma, and COPD.
- Liquidity Runway: Management believes the $142.6 million in cash and marketable securities is sufficient to fund operations for at least the next 12 months from the filing date.
- Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to Legacy Inmagene's period-end reporting process, specifically regarding segregation of duties for journal entries and account reconciliations. Remediation plans are underway.
- Legal Proceedings: Two shareholder lawsuits were filed in June 2025 challenging the merger registration statement. The company intends to vigorously defend against these claims.
- Supply Chain Risks: The company relies on a single-source manufacturer in China (WuXi Biologics) for IMG-007. Potential U.S. legislative actions (e.g., BIOSECURE Act) and tariffs pose risks to the supply chain.
Key Facts for Investor Verification
- Merger Accounting: Verify the treatment of the reverse recapitalization and the specific impact of the $15.3 million stock-based compensation charge on the Q3 2025 loss.
- Non-OX40 Divestiture: Review the terms of the $8.9 million promissory note received from the related party (BuyCo) and the associated Contingent Value Rights (CVR) liability.
- Internal Controls: Monitor the progress of remediation for the identified material weakness in financial reporting controls.
- Manufacturing Dependency: Assess the risks associated with reliance on a single Chinese manufacturer for the lead asset in the context of evolving U.S. trade and national security policies.
- Cash Burn Rate: Evaluate the sustainability of the current cash position given the high operating costs associated with clinical development and public company compliance.